LSV Asset Management Lowers Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

LSV Asset Management cut its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,089,300 shares of the company's stock after selling 340,000 shares during the quarter. LSV Asset Management owned approximately 0.36% of Amneal Pharmaceuticals worth $6,612,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Rubric Capital Management LP boosted its position in Amneal Pharmaceuticals by 54.7% during the third quarter. Rubric Capital Management LP now owns 4,024,500 shares of the company's stock valued at $16,983,000 after purchasing an additional 1,423,121 shares in the last quarter. Phocas Financial Corp. bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $4,339,000. Vanguard Group Inc. lifted its position in Amneal Pharmaceuticals by 3.1% during the third quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company's stock valued at $57,174,000 after acquiring an additional 412,599 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Amneal Pharmaceuticals by 122.4% in the third quarter. Assenagon Asset Management S.A. now owns 515,233 shares of the company's stock valued at $2,174,000 after acquiring an additional 283,524 shares in the last quarter. Finally, EAM Investors LLC purchased a new position in Amneal Pharmaceuticals in the third quarter worth $972,000. 31.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AMRX has been the topic of several recent analyst reports. Barclays upped their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an "overweight" rating in a research report on Monday, January 29th. Piper Sandler raised their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an "overweight" rating in a report on Thursday, March 21st. StockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, March 4th. The Goldman Sachs Group lifted their price target on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Truist Financial reissued a "buy" rating and issued a $9.00 price objective (up from $7.00) on shares of Amneal Pharmaceuticals in a report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $8.25.

Amneal Pharmaceuticals Stock Performance

AMRX traded down $0.12 during midday trading on Thursday, hitting $6.47. 809,076 shares of the company were exchanged, compared to its average volume of 1,553,112. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -11.77 and a beta of 1.33. The company's 50 day simple moving average is $5.79 and its 200 day simple moving average is $5.34. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals, Inc. has a 1-year low of $1.74 and a 1-year high of $6.90.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. The company had revenue of $616.98 million during the quarter, compared to analysts' expectations of $630.67 million. As a group, sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.